1192548-08-5

Basic information

• Product Name: 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;2-Fluoro-3-methylphenylboronic acid, pinacol ester;2-Fluoro-4-forMylphenyl-3-Methyl-boronic acid pinacol ester, 97%;2-Fluoro-3-Methylbenzeneboronic acid pinacol ester, 96%
• CAS NO: 1192548-08-5
• Molecular Formula: C₁₃H₁₈BFO₂
• Molecular Weight: 236.0902232
• Mol File: 1192548-08-5.mol

Chemical Properties

• Boiling Point: 308.5±35.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.04±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1192548-08-5)
• EPA Substance Registry System: 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1192548-08-5)

Safety Data

• Hazardous Substances Data: 1192548-08-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is used as a reagent for the preparation of FASN inhibitors. These inhibitors are crucial in the treatment of cancer and other diseases, as they target the fatty acid synthase enzyme, which plays a significant role in the growth and survival of cancer cells.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is employed as a reagent for the fluorine-controlled carbon-hydrogen borylation of arenes. This process is catalyzed by a phosphorus-silicon-nitrogen-pincer platinum complex, allowing for the selective functionalization of aromatic compounds and the formation of valuable intermediates for further chemical transformations.
Overall, 2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is a valuable compound in both the pharmaceutical and chemical synthesis industries due to its unique properties and reactivity. Its applications in the development of FASN inhibitors and its role in the synthesis of various organic compounds make it an important tool in the advancement of medical treatments and chemical research.

Upstream product

• 95-52-3 2-Fluorotoluene 
• 73183-34-3 bis(pinacol)diborane 
• 452-66-4 5-chloro-2-fluorotoluene 

Relevant articles and documents

Chiral Atropisomeric Indenocorannulene Bowls: Critique of the Cahn–Ingold–Prelog Conception of Molecular Chirality

Chiral corannulenes abound, but suffer generally from configurational lability associated with bowl-to-bowl inversion, thus obviating questions of stereogenicity and stereoelement construction. In contrast, peri-annulated corannulenes show greatly increas

Fluorine-controlled C-H borylation of arenes catalyzed by a PSiN-pincer platinum complex

An efficient, regioselective synthesis of fluorine-substituted arylboronic esters was achieved through fluorine-controlled C-H borylation of arenes with diboron catalyzed by a PSiN-platinum complex. The promising utility of the PSiN-platinum catalyst and its unique regioselectivity were demonstrated for the first time, which would complement the well-developed Ir-catalyzed C-H borylation.

METHODS FOR PRODUCING BORYLATED ARENES

Methods for the selective borylation of arenes, including arenes substituted with an electron-withdrawing group (e.g., 1-chloro-3-fluoro-2-substituted benzenes) are provided. The methods can be used, in some embodiments, to efficiently and regioselectivel

A catalytic borylation/dehalogenation route to o -fluoro arylboronates

A two-step Ir-catalyzed borylation/Pd-catalyzed dehalogenation sequence allows for the net synthesis of fluoroarenes where the boronic ester is ortho to fluorine. Key elements of this approach include the use of a halogen para to the fluorine to block meta Ir-catalyzed borylation and the chemoselective Pd-catalyzed dehalogenation by KF activated polymethylhydrosiloxane (PMHS).

AMINO ACID COMPOUNDS

[Problem] To provide novel compounds that are S1P1 receptor agonists and exhibit an immunosuppressive activities by inducing lymphocyte sequestration in secondary lymphoid tissues. In addition, to provide a pharmaceutical agent which comprises the compounds as an effective component, in particular to provide a therapeutic and/or prophylactic agent for an autoimmune disease and the like. [Solving Means] Amino acid compounds that are represented by the following Formula (1) are provided